Joseph P. Hagan - 30 Jan 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RGLS
Reported as of: 30 Jan 2025
Net transaction value: +$54,260
SEC form: 4
Accepted by SEC: 31 Jan 2025, 17:00:10 UTC
Prior SEC filing: 15 Jan 2025
Next SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: Christopher Aker, Attorney in Fact

Key filing fact

Joseph P. Hagan filed Form 4 for Regulus Therapeutics Inc. (RGLS) on 31 Jan 2025.

Key facts

This page summarizes Joseph P. Hagan's Form 4 filing for Regulus Therapeutics Inc. (RGLS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Jan 2025, 17:00.

Change

Previous filing in this sequence was filed on 15 Jan 2025.
Current net transaction value: +$54,260.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGLS transaction

Common Stock

Purchase

Transaction value: $54,260
Shares: +50,000
Change %: +24%
Price: $1.09
Shares after: 260,808
Date: 30 Jan 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,350,000
Change %
Price: $0.000000
Shares after: 1,350,000
Date: 30 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,350,000
Exercise price: $1.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The weighted average purchase price for the transaction reported was $1.0852, and the range of prices were between $1.065 and $1.0897. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.

Footnote F2

The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.